Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
Chembio Diagnostics has launched a rapid point-of-care test for detecting COVID-19 antigens and Flu A and B from a single patient sample. This test, which has received FDA Emergency Use Authorization, takes just 15 minutes to provide results and is available for immediate shipment across the United States. It is designed for use in various testing environments and can help differentiate between COVID-19 and influenza infections efficiently. The test is an essential tool as the healthcare industry prepares for transitioning COVID-19 to an endemic state.
- Rapid point-of-care test for COVID-19 and Flu A/B launched.
- Results produced in just 15 minutes without the need for instrumentation.
- FDA Emergency Use Authorization received for the test.
- Immediate availability of product inventory for customers.
- None.
In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes
HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States.
The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.
“As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,” said Charles Caso, Vice President of Sales and Marketing for Chembio. “Based on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.”
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.
Contact:
Brian Johnston
Gilmartin Group
631-807-1986
investor@chembio.com
FAQ
What is the new point-of-care test launched by Chembio Diagnostics?
What authorization has the new Chembio test received?
How quickly can results be obtained from the new COVID-19/Flu A/B test?
Is the Chembio rapid test available for immediate use?
What does the Chembio test differentiate between?
